Shaheenah Dawood, Consultant Medical Oncologist at Mediclinic Middle East, shared a post on LinkedIn:
“Hot off the press!
- adjuvant Selpercatinib led to a statistically significant and clinically meaningful improvement in efs vs placebo in the treatment of patients with early-stage RET fusion–positive NSCLC
- primary end point met of the phase 3 LIBRETTO-432 trial.”
Title: BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer
Authors: Timothé Guinela, Amélie Lusqueb, Audrey Mailliez, Vincent Massard, William Jacot, Severine Guiue, Thibault de la Motte Rouge, Etienne Braing, Isabelle Desmoulinsh, Monica Arnedos, Caroline Bailleux, Anthony Goncalves, Christelle Levy, Thomas Bachelot, Lise Bosquet, Suzette Delaloge, Jean-Sébastien Frénel
Read the Full Article.
Other articles featuring Shaheenah Dawood.
